Literature DB >> 9787177

Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells.

N Voorzanger-Rousselot1, M Favrot, J Y Blay.   

Abstract

The modulation of the cytotoxic effects of an anthracyclin by CD40L was investigated in five non-Hodgkin's lymphoma (NHL) cell lines (Daudi, Raji, BJAB, BL36, BL70). Incubation with doxorubicin (DOX) increased in a dose-dependent manner the percentage of apoptosis in NHL cells. Coculture with irradiated L cells expressing CD40L (CD40L L cells), but not CDw32 (CDw32 L cells), significantly reduced (33% to 89%) the percentage of apoptosis in all five cell lines treated with 0.1 to 0.5 microgram/mL of DOX, but in only three cell lines at 1 microgram/mL. Interleukin-10 (IL-10), IL-6, IL-2, or tumor necrosis factor (TNF) induced no additive protective effects with CD40L L cells. In all five cell lines, DOX induced a concentration-dependent increase of the activity of the cysteine-protease caspase 3. Coculture with CD40L L cells, but not with CDw32 L cells, inhibited (38% to 100%) the activation of caspase 3 induced by 0.1 to 0.5 microgram/mL of DOX in all five NHL cell lines, but in only two cell lines at 1 microgram/mL. Finally, the antiproliferative effect of 0.1 to 0.5 microgram/mL concentrations of DOX was also partially abrogated on coculture with CD40L L cells in all five cell lines, but in only two cell lines at 1 microgram/mL. Cytokines, either alone or in combination with CD40L L cells, did not affect DOX-induced inhibition of proliferation. These results indicate that CD40L inhibits the apoptosis and antiproliferative effect induced by DOX and interferes with caspase 3 activation in B NHL cell lines. Copyright 1998 by The American Society of Hematology

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787177

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells.

Authors:  Daeho Cho; Young-In Kim; Jae Seung Kang; Eunsil Hahm; Yoolhee Yang; Daejin Kim; Seonghan Kim; Yeong Seok Kim; Daeyoung Hur; Hyunjeong Park; Young Il Hwang; Tae-Sung Kim; Wang Jae Lee
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

2.  Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo.

Authors:  C Knörr; C Amrehn; H Seeberger; A Rosenwald; S Stilgenbauer; G Ott; H K Müller Hermelink; A Greiner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

4.  Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.

Authors:  M Chin; M Herscovitch; N Zhang; D J Waxman; T D Gilmore
Journal:  Oncogene       Date:  2009-04-20       Impact factor: 9.867

5.  Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Authors:  Indu R Ramachandran; Thomas Condamine; Cindy Lin; Sarah E Herlihy; Alfred Garfall; Dan T Vogl; Dmitry I Gabrilovich; Yulia Nefedova
Journal:  Cancer Lett       Date:  2015-11-27       Impact factor: 8.679

6.  CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways.

Authors:  Nathalie Voorzanger-Rousselot; Laurent Alberti; Jean-Yves Blay
Journal:  BMC Cancer       Date:  2006-03-18       Impact factor: 4.430

7.  Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.

Authors:  C M Galmarini; N Falette; E Tabone; C Levrat; R Britten; N Voorzanger-Rousselot; O Roesch-Gateau; A Vanier-Viornery; A Puisieux; C Dumontet
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

Review 8.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

9.  Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody.

Authors:  Angélique Gougelet; Adeline Mansuy; Jean-Yves Blay; Laurent Alberti; Claudine Vermot-Desroches
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

10.  Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Authors:  Guoqi Song; Huiyun Ni; Linqing Zou; Shukui Wang; Fuliang Tian; Hong Liu; William C Cho
Journal:  Onco Targets Ther       Date:  2016-06-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.